Scholar Rock Holding Corporation filings document the public-company record of a Nasdaq-listed biopharmaceutical issuer focused on apitegromab, spinal muscular atrophy, and myostatin biology programs. Current reports on Form 8-K cover operating and financial results, Regulation FD business updates, apitegromab regulatory disclosures, preliminary cash updates, and amendments correcting furnished earnings materials.
The company’s SEC record also includes proxy materials for director elections, auditor ratification, and advisory executive-compensation votes. Capital-structure disclosures identify SRRK common stock listed on the Nasdaq Global Select Market and include shelf registration and at-the-market offering materials for common stock sales.
Scholar Rock Holding Corp's Chief Operating Officer, R. Keith Woods, reported a sale of common stock that was executed solely to cover taxes on recently vested performance-based restricted stock units (PSUs). On January 13, 2026, he sold 16,746 shares of common stock at $42.70 per share in a mandated "sell to cover" transaction under the company’s equity incentive plans, rather than a discretionary trade.
These shares relate to PSU awards granted on April 27, 2025, with 50,000 PSU shares vesting on January 12, 2026 and additional tranches scheduled through April 27, 2029 if service and performance conditions are met. After the tax-related sale, Woods has beneficial ownership of 583,254 share-based interests, consisting of 33,254 shares of common stock, 100,000 time-based RSUs and 450,000 PSUs.
Scholar Rock Holding Corp director and President of R&D Akshay Vaishnaw reported a mandatory tax-related share sale. On 01/13/2026, he sold 20,438 shares of common stock at $42.70 per share in a transaction coded "S." According to the notes, this was a "sell to cover" sale required to satisfy tax withholding from vesting performance- and time-based restricted stock units (PSUs), and is not a discretionary trade.
After the transaction, he beneficially owned 595,767 common share equivalents. This consists of 45,767 shares of common stock, 100,000 restricted stock units, and 450,000 PSUs that vest over time and based on Scholar Rock’s stock price performance, with unvested PSUs forfeited if not vested by April 27, 2029.
Scholar Rock Holding Corp Chief Executive Officer and director David Hallal reported a mandatory share sale linked to equity award vesting. On 01/13/2026, he sold 57,450 shares of common stock at $42.7 per share, solely to cover tax withholding arising from the vesting of performance- and time-based restricted stock units (PSUs) under the company’s equity incentive plans. The transaction was executed as a required “sell to cover” through a designated broker and is noted as not being a discretionary trade.
The vested shares relate to PSU awards granted on April 27, 2025, with 125,000 shares vesting on January 12, 2026, another 125,000 scheduled to vest on April 27, 2027, and additional tranches tied to future stock price and service-based conditions through April 27, 2029, after which any unvested PSUs are forfeited. Following the reported sale, Hallal directly holds 1,541,645 shares of common stock, and a further 205,000 shares are held indirectly by the Hallal Family Irrevocable Trust – 2012, where his spouse serves as trustee and beneficial ownership is disclaimed except for any pecuniary interest.
Scholar Rock Holding Corporation reported preliminary financial and business updates, including an estimated unaudited cash, cash equivalents and marketable securities balance of approximately $365 million as of December 31, 2025. The company has not yet finalized its full fourth-quarter and full-year 2025 results, and the ongoing audit could change these preliminary figures.
The company also issued a press release with business updates and more detail on its 2026 strategic priorities, furnished as Exhibit 99.1, and prepared a corporate presentation for meetings at the 44th Annual J.P. Morgan Healthcare Conference, filed as Exhibit 99.2. The update includes forward-looking statements about its growth strategy, clinical programs, regulatory timelines, commercial launch expectations, a cash runway into 2027, and other operational milestones, all subject to risks outlined in its most recent quarterly report.
Scholar Rock Holding Corp director reports tax-related stock sales. A company director filed a Form 4 for two sales of common stock on 12/16/2025. The director sold 726 shares at a weighted average price of $43.8761, with individual trade prices ranging from $43.39 to $44.38. A second sale covered 280 shares at a weighted average price of $44.6344, with prices ranging from $44.39 to $45.23. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units. Following the transactions, the director beneficially owns 32,908 equity awards, consisting of 14,844 shares of common stock and 18,064 restricted stock units (RSUs), all held directly.
Scholar Rock Holding Corp director Srinivas Akkaraju reported multiple transactions in the company’s common stock. On 10/07/2025, he indirectly purchased 12,796, 12,400 and 4,403 shares through Samsara Opportunity Fund, L.P. at weighted average prices of $39.31, $40.18 and $40.97 per share, increasing that fund’s indirect holdings to 530,038 shares.
On 12/12/2025, warrants with a $7.35 exercise price were exercised through Samsara BioCapital, L.P., resulting in the acquisition of 1,064,804 shares of common stock and raising that entity’s indirect holdings to 6,367,614 shares, with the related warrant position reduced to zero. The form also shows 21,132 shares of common stock held directly. Footnotes explain that the 10/07/2025 purchase prices are weighted averages for multiple trades within specified price ranges.
Scholar Rock Holding Corporation announced it filed a prospectus supplement for its at-the-market offering program, permitting the offer and sale, from time to time at its sole discretion, of additional shares of common stock with an aggregate offering price of up to $200,000,000. Sales will be conducted through Jefferies LLC as sales agent under the company’s automatically effective shelf registration statement on Form S-3ASR.
Offerings of these shares will be made only by means of the prospectus supplement and the base prospectus. The company also filed a legal opinion from Goodwin Procter LLP as an exhibit. This update provides ongoing access to equity capital via an established ATM facility, allowing the company to sell small amounts of stock into the market as conditions permit.
Scholar Rock Holding Corporation launched an at‑the‑market offering of its common stock, allowing sales of up to $200,000,000 from time to time through Jefferies LLC acting as agent. Sales, if any, will be made pursuant to Rule 415(a)(4) and Jefferies will use commercially reasonable efforts; there is no obligation to sell a minimum amount.
Jefferies will receive up to 3.0% of gross proceeds as commissions and will be deemed an underwriter. Net proceeds are intended to support commercialization of apitegromab, advance clinical programs and the platform, and for working capital and general corporate purposes. SRRK is listed on Nasdaq; the common stock last closed at $30.82 on November 12, 2025. Shares outstanding were 99,171,486 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Scholar Rock (SRRK) reported Q3 2025 results with a larger loss as it prepares for potential commercialization. Net loss was $102.2 million for the quarter and $287.0 million for the nine months. Operating expenses rose to $103.6 million in Q3, driven by higher R&D to support apitegromab and pipeline work, and sharply higher G&A for launch readiness, equity-based comp, and professional services.
Liquidity remains solid. Cash, cash equivalents and marketable securities totaled $369.6 million as of September 30, 2025, with long‑term debt of $99.6 million. The company raised $91.7 million net through its ATM in 2025 (2,767,000 shares) and drew an additional $50.0 million term loan on September 29, bringing total term loans funded to $100.0 million. Shares outstanding were 102,007,457 as of November 5, 2025.
Regulatory update: The FDA issued a Complete Response Letter in September tied to site‑related observations at a third‑party fill‑finish facility; no efficacy or safety issues were cited. Scholar Rock held a Type A meeting in November and plans to resubmit the apitegromab BLA when the facility is reclassified. The EMA validated the apitegromab MAA in March 2025.
Scholar Rock Holding Corporation (SRRK) furnished an update regarding its quarterly results process. The company issued a press release with financial and operating results for the quarter ended September 30, 2025, furnished as Exhibit 99.1.
It also furnished presentation slides as Exhibit 99.2 for a conference call scheduled for 8:00 am ET on November 14, 2025. The press release and slides are furnished, not filed, under the Exchange Act.